Multaq Lawsuit Filed Over Failure to Warn About Liver Injury Risks

|

Sanofi-Aventis faces a product liability lawsuit filed by multiple plaintiffs, which alleges that the drug maker withheld information about the risk of serious liver injury associated with side effects of Multaq. 

The complaint (PDF) was filed in the U.S. District Court for the Middle District of North Carolina on January 25, by Ruth Amanda Hardin and Michael Clay, both of North Carolina, Eric Biggs of Pennsylvania, Virginia Roberts of Oklahoma, and by Mary Jo Meyer of Indiana, who brought a claim on behalf of herself and the estate of James Meyer.

Hardin, Biggs, and James Meyer suffered serious drug-induced liver injuries due to the use of Multaq. Clay suffered liver damage, heart failure and other cardiovascular problems.

Hair-Dye-Cancer-Lawsuits
Hair-Dye-Cancer-Lawsuits

Multaq (dronedarone) is a prescription treatment for abnormal heart rhythms, which was introduced by Sanofi-Aventis in July 2009.

In January 2011, the FDA required new warnings about the potential risk of liver failure or liver injury from Multaq, indicating that at least two patients on Multaq suffered acute liver failure that required them to get a liver transplant.

In December 2011, the FDA issued another Multaq safety warning, advising that the drug should not be used in patients whose abnormal heart rhythms were permanent. It also required the manufacturer, Merck & Co., to add additional safety warnings and contraindications to the label.

“Plaintiffs allege that Defendants had an established duty to warn of the dangers of using Multaq. Defendants knew or should have known of the dangers generally known to the scientific community at the time they manufactured and distributed Multaq,” the lawsuit filed this week indicates. “Defendants failed to provide warning of the dangers of using Multaq, specifically failing to warn Plaintiffs and their physicians regarding known dangers including the danger of life-threatening liver and cardiovascular injuries.”

The complaint presents claims against the drug maker for failure to warn, designing a defective drug, negligence, and breach of warranty, seeking both compensatory and punitive damages.


0 Comments


Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

MORE TOP STORIES

In the six months since a Bard hernia mesh settlement agreement was reached, at least two dozen new lawsuits have been brought, as the implants continue to fail and require revision surgery.
As new BioZorb lawsuits continue to be filed over complications with the recalled breast tissue markers, lawyers indicate they are on track for the first of four test cases to go before a jury in September 2025.
Women pursuing Depo-Provera meningioma lawsuits will have to provide documentary proof of their diagnosis and the versions of the birth control shot they received within 120 days of filing their case.